Replies to post #126817 on Biotech Values

[DewDiligence]

…I predict a Novartis munch [of MNTA] within 12 months. Cash+CVR's [contingent value rights] for Copaxone.

The FDA’s willingness to approve Amphastar’s Lovenox would seem to increase the likelihood to some degree that the FDA will approve MNTA’s Copaxone, and that’s how I would expect MNTA’s BoD to view the situation. Thus, there may be strong resistance to the idea of accepting a lowball up-front with a CVR for Copaxone.

[jb_118]

I'll go on record and predict a Novartis munch within 12 months. Cash+CVR's for Copaxone.

If so, it may help explain why NVS has declined to partner with MNTA on FOB, if in fact they think it has value. Why drive the buyout price up?

[DewDiligence]

MNTA—I'll go on record and predict a Novartis munch within 12 months [i.e. before 9/20/12] Cash+CVR's for Copaxone.

Do you still expect such an outcome?